Non-exudative Type 1 MNV and AMD: protect vision with smarter imaging
Official title: The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) Progression
Funded at Utah State Higher Education System--University of Utah · NIH-11418359 · Data updated 2026-11-12
This project studies how a specific, non-exudative form of eye blood vessels in AMD might help preserve vision, using advanced eye imaging and patient-friendly tests.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Utah State Higher Education System--University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | September 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $385,000 |
| NIH project number | 5R01EY033365-05 |
| Project ID | NIH-11418359 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with AMD who have or are suspected to have non-exudative type 1 MNV and can undergo high-resolution retinal imaging and perimetry.
✕Less likely to help
Patients without non-exudative type 1 MNV or those unable to complete imaging or perimetry may not benefit.
What this research studies
In people with age-related macular degeneration, the research will look at non-exudative type 1 MNV and how it may slow nearby retinal damage. The study combines high-resolution retinal imaging with precise, patient-friendly tests of visual function to map where the retina stays healthier. By focusing on spatially-resolved measurements, researchers hope to pinpoint patterns of preserved function and structure around the MNV area. The goal is to gather evidence that could guide future, less burdensome assessments for patients and improve understanding of AMD progression.
Why it matters
Potential benefit: If successful, the work could lead to better ways to monitor AMD and potentially extend useful vision in patients.
How similar studies have gone: Previous studies suggest non-exudative MNV may be associated with slower retinal degeneration, but direct protective effects on function need confirmation.
Where this research is happening
-
Utah State Higher Education System--University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Fleckenstein, Monika — Utah State Higher Education System--University of Utah
- Study coordinator: Fleckenstein, Monika
Related research
Other NIH-funded projects on the same topics.
-
AI-powered tool to predict 2-year risk of late AMD
A new AI software helps people at risk of age-related macular degeneration understand their 2-year risk and what steps could protect their vision.
-
Active cycling program to support vision and daily living in Veterans with AMD
A 6-month online group spin cycling program is tested to help Veterans with age-related macular degeneration maintain vision and improve daily functioning.
-
Transplanting stem-cell–derived retinal cells to treat dry AMD
A medical team is testing a stem cell therapy to replace damaged retinal cells in adults with dry age-related macular degeneration.
-
RPESC-derived RPE Transplant for Dry AMD in adults
A new cell-based therapy derived from RPESCs is being tested to help adults with dry age-related macular degeneration regain vision.
-
New high-resolution OCT biomarkers to map early AMD changes
A new imaging approach using advanced OCT methods will help doctors see early changes in age-related macular degeneration to guide treatment and improve quality of life for older adults.
-
Targeting inflammation in age-related macular degeneration
Aims to understand how inflammation drives age-related macular degeneration in people and explore new targets to slow or stop vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.